Text and Data Mining valid from 2017-05-17
Received: 9 January 2017
Accepted: 12 April 2017
First Online: 17 May 2017
Change Date: 19 June 2017
Change Type: Correction
Change Details: The Reviewer Information section was corrected.
: S.R.-R., X.W. and J.L. are employees of Novo Nordisk, a pharmaceutical company focused on class B GPCRs for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. The other authors declare no competing financial interests.